Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
ROCK2 inhibitor

Belumosudil

Brand names: Rezurock

Belumosudil is an oral kinase inhibitor used to treat chronic graft-versus-host disease after failure of earlier lines of systemic therapy.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It inhibits Rho-associated coiled-coil kinase 2 (ROCK2), modulating the immune response and reducing the inflammatory and fibrotic processes that drive chronic graft-versus-host disease.

Prescribing in practice

  • It can raise liver enzymes, so liver function should be checked before and during treatment.
  • Strong CYP3A inducers reduce its exposure, so concomitant medicines should be reviewed for interactions.
  • Infection, nausea and fatigue are recognised effects in this immunosuppressed population.

Monitoring

Monitor liver function tests periodically and remain alert for signs of infection.

Counselling the patient

  • Take the medicine with food as advised.
  • Report signs of infection or yellowing of the skin or eyes.
  • Tell your team about all other medicines, as some can interact.

Evidence & guidelines

Belumosudil is supported by trial evidence showing meaningful response rates in chronic graft-versus-host disease after prior systemic therapy.

Reference: NICE TA evaluation; BSH; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways